Kayne Anderson Rudnick Investment Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.87M | Buy |
20,704
+990
| +5% | +$82.9K | 0.01% | 349 |
|
|
2026
Q1 | $1.58M | Buy |
19,714
+7,131
| +57% | +$588K | ﹤0.01% | 342 |
|
|
2025
Q4 | $1.07M | Buy |
12,583
+3,913
| +45% | +$321K | ﹤0.01% | 382 |
|
|
2025
Q3 | $674K | Buy |
8,670
+5,146
| +146% | +$402K | ﹤0.01% | 414 |
|
|
2025
Q2 | $276K | Buy |
3,524
+583
| +20% | +$43.5K | ﹤0.01% | 479 |
|
|
2025
Q1 | $213K | Buy |
2,941
+1,916
| +187% | +$137K | ﹤0.01% | 479 |
|
|
2024
Q4 | $75.9K | Sell |
1,025
-62,335
| -98% | -$4.36M | ﹤0.01% | 518 |
|
|
2024
Q3 | $4.18M | Sell |
63,360
-1,873
| -3% | -$136K | 0.01% | 282 |
|
|
2024
Q2 | $6.03M | Sell |
65,233
-1,432
| -2% | -$127K | 0.01% | 270 |
|
|
2024
Q1 | $6.37M | Sell |
66,665
-2,356
| -3% | -$198K | 0.01% | 274 |
|
|
2023
Q4 | $5.26M | Buy |
69,021
+19,750
| +40% | +$1.37M | 0.01% | 288 |
|
|
2023
Q3 | $3.41M | Sell |
49,271
-364
| -0.7% | -$29.3K | 0.01% | 317 |
|
|
2023
Q2 | $4.68M | Sell |
49,635
-719
| -1% | -$62.5K | 0.01% | 298 |
|
|
2023
Q1 | $4.17M | Buy |
50,354
+975
| +2% | +$76.6K | 0.01% | 301 |
|
|
2022
Q4 | $3.68M | Sell |
49,379
-2,090
| -4% | -$161K | 0.01% | 312 |
|
|
2022
Q3 | $4.25M | Buy |
+51,469
| New | +$4.95M | 0.01% | 293 |
|
|
2022
Q2 | – | Sell |
-40
| Closed | -$5K | – | 627 |
|
|
2022
Q1 | $5K | Buy |
+40
| New | +$4.49K | ﹤0.01% | 564 |
|
|
2020
Q3 | – | Sell |
-63
| Closed | -$4K | – | 538 |
|
|
2020
Q2 | $4K | Hold |
63
| – | – | ﹤0.01% | 465 |
|
|
2020
Q1 | $4K | Hold |
63
| – | – | ﹤0.01% | 466 |
|
|
2019
Q4 | $5K | Hold |
63
| – | – | ﹤0.01% | 454 |
|
|
2019
Q3 | $5K | Hold |
63
| – | – | ﹤0.01% | 427 |
|
|
2019
Q2 | $4K | Buy |
+63
| New | +$3.81K | ﹤0.01% | 440 |
|
|
2017
Q1 | – | Sell |
-64,197
| Closed | -$2M | – | 337 |
|
|
2016
Q4 | $2M | Buy |
64,197
+5,067
| +9% | +$164K | 0.02% | 254 |
|
|
2016
Q3 | $2.38M | Buy |
59,130
+6,033
| +11% | +$227K | 0.03% | 237 |
|
|
2016
Q2 | $1.76M | Sell |
53,097
-9,966
| -16% | -$341K | 0.03% | 244 |
|
|
2016
Q1 | $1.85M | Buy |
63,063
+7,107
| +13% | +$196K | 0.03% | 231 |
|
|
2015
Q4 | $1.47M | Sell |
55,956
-30,342
| -35% | -$788K | 0.02% | 242 |
|
|
2015
Q3 | $2.04M | Buy |
86,298
+5,670
| +7% | +$137K | 0.03% | 209 |
|
|
2015
Q2 | $1.91M | Buy |
80,628
+10,626
| +15% | +$240K | 0.03% | 218 |
|
|
2015
Q1 | $1.66M | Sell |
70,002
-1,674
| -2% | -$37.6K | 0.03% | 225 |
|
|
2014
Q4 | $1.52M | Sell |
71,676
-5,664
| -7% | -$114K | 0.03% | 229 |
|
|
2014
Q3 | $1.32M | Sell |
77,340
-21,492
| -22% | -$339K | 0.02% | 232 |
|
|
2014
Q2 | $1.41M | Sell |
98,832
-6,942
| -7% | -$94.1K | 0.02% | 223 |
|
|
2014
Q1 | $1.31M | Buy |
105,774
+7,914
| +8% | +$91.3K | 0.02% | 225 |
|
|
2013
Q4 | $1.07M | Buy |
97,860
+26,916
| +38% | +$303K | 0.02% | 227 |
|
|
2013
Q3 | $823K | Buy |
+70,944
| New | +$830K | 0.02% | 232 |
|
Other funds holding EW
Kayne Anderson Rudnick Investment Management's EW Position: Q2 2026 in Review
Kayne Anderson Rudnick Investment Management increased its Edwards Lifesciences (EW) stake by 5% in Q2 2026, buying an estimated $82.9K and bringing the position to 20,704 shares worth $1.87M. The position accounts for 0.01% of the portfolio, ranked #349.
Kayne Anderson Rudnick Investment Management first reported a position in EW in Q3 2013 and has held it in 36 quarters since. The position peaked at $6.37M in Q1 2024. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Kayne Anderson Rudnick Investment Management held 20,704 shares of Edwards Lifesciences worth $1.87M as of Q2 2026.
- Kayne Anderson Rudnick Investment Management bought 990 Edwards Lifesciences shares in Q2 2026, an estimated $82.9K.
- Edwards Lifesciences made up 0.01% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #349 holding.
- Kayne Anderson Rudnick Investment Management first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 36 quarters since.
- Kayne Anderson Rudnick Investment Management's Edwards Lifesciences position peaked at $6.37M in Q1 2024.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.